Mankind Pharma Ltd. (IN:MANKIND)
:MANKIND
Want to see IN:MANKIND full AI Analyst Report?
Top Page
Mankind Pharma Ltd.
(MANKIND)
Select Model
Select Model
Rating:59Neutral
Price Target:
₹2,110.00
▼(-4.20% Downside)
Action:ReiteratedDate:11/08/25
Mankind Pharma's strong financial performance is the most significant positive factor, showcasing robust growth and operational efficiency. However, the stock's technical indicators suggest bearish momentum, and the high P/E ratio indicates potential overvaluation, which are key risks impacting the overall score.
Positive Factors
Revenue Growth
Sustained high revenue growth indicates expanding product adoption and effective commercial execution in core therapy areas. Durable top-line expansion supports continued reinvestment into marketing, product launches and scale benefits that can compound margins and address multiple therapy segments over 2–6 months and beyond.
Negative Factors
Earnings Decline
A material negative EPS print despite revenue growth signals margin pressure, one-offs, or rising costs that erode shareholder earnings. Persistent EPS weakness can reduce reinvestment capacity and investor confidence and may indicate underlying profitability volatility over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained high revenue growth indicates expanding product adoption and effective commercial execution in core therapy areas. Durable top-line expansion supports continued reinvestment into marketing, product launches and scale benefits that can compound margins and address multiple therapy segments over 2–6 months and beyond.
Read all positive factors
Mankind Pharma Ltd. (MANKIND) vs. iShares MSCI India ETF (INDA)
Market Cap
₹935.47B
Dividend Yield0.04%
Average Volume (3M)10.08K
Price to Earnings (P/E)55.5
Beta (1Y)0.49
Revenue Growth19.53%
EPS Growth-15.32%
CountryIN
Employees19,540
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)12.10
Shares Outstanding412,828,340
10 Day Avg. Volume5,924
30 Day Avg. Volume10,081
Financial Highlights & Ratios
PEG Ratio16.80
Price to Book (P/B)6.94
Price to Sales (P/S)8.15
P/FCF Ratio50.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹2,800.00Price Target Upside27.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)57.57
Revenue Forecast (FY)₹159.53B
Mankind Pharma Ltd. Business Overview & Revenue Model
Company Description
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products primarily in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of...
How the Company Makes Money
Mankind Pharma primarily makes money by selling pharmaceutical and healthcare products, with revenue driven mainly by branded formulations sold in India. Its key revenue stream is the domestic sale of prescription medicines to distributors/stockis...
Mankind Pharma Ltd. Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
80
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 134.74B | 122.07B | 102.59B | 87.49B | 77.82B | 62.14B |
| Gross Profit | 84.33B | 86.38B | 70.02B | 57.87B | 53.12B | 43.89B |
| EBITDA | 37.54B | 35.58B | 28.04B | 20.37B | 21.97B | 18.30B |
| Net Income | 17.51B | 19.91B | 19.13B | 12.82B | 14.33B | 12.65B |
Balance Sheet | ||||||
| Total Assets | 288.13B | 277.60B | 119.63B | 97.15B | 91.48B | 63.73B |
| Cash, Cash Equivalents and Short-Term Investments | 31.05B | 22.45B | 34.56B | 15.29B | 12.79B | 20.04B |
| Total Debt | 83.69B | 85.11B | 2.07B | 1.70B | 8.73B | 2.41B |
| Total Liabilities | 132.85B | 131.91B | 23.87B | 20.67B | 28.31B | 15.10B |
| Stockholders Equity | 152.86B | 143.32B | 93.63B | 74.35B | 61.55B | 47.22B |
Cash Flow | ||||||
| Free Cash Flow | 13.66B | 19.53B | 17.70B | 9.53B | -14.26B | 8.25B |
| Operating Cash Flow | 16.37B | 24.13B | 21.52B | 17.85B | 9.20B | 11.37B |
| Investing Cash Flow | -11.68B | -126.92B | -20.82B | -10.54B | -13.69B | -12.22B |
| Financing Cash Flow | -5.49B | 102.33B | 52.66M | -7.40B | 6.05B | -78.11M |
Mankind Pharma Ltd. Technical Analysis
Neutral
2202.55
Price Trends
2093.13
Positive
2139.76
Negative
2311.77
Negative
Market Momentum
-0.87
Negative
56.56
Neutral
87.08
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MANKIND, the sentiment is Neutral. The current price of 2202.55 is above the 20-day moving average (MA) of 2040.49, above the 50-day MA of 2093.13, and below the 200-day MA of 2311.77, indicating a neutral trend. The MACD of -0.87 indicates Negative momentum. The RSI at 56.56 is Neutral, neither overbought nor oversold. The STOCH value of 87.08 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:MANKIND.
Mankind Pharma Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ₹639.49B | 25.97 | ― | 0.80% | 11.73% | 10.02% | |
72 Outperform | ₹1.06T | 20.49 | ― | 0.57% | 18.86% | 61.69% | |
72 Outperform | ₹937.66B | 22.07 | ― | 1.19% | 17.27% | 8.99% | |
71 Outperform | ₹4.16T | 30.62 | ― | 0.91% | 10.09% | -4.53% | |
66 Neutral | ₹1.43T | 51.30 | ― | 0.84% | 12.74% | 22.02% | |
59 Neutral | ₹935.47B | 55.46 | ― | 0.04% | 19.53% | -15.32% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:MANKIND
Mankind Pharma Ltd.
2,269.95
-286.24
-11.20%
IN:ALKEM
Alkem Laboratories Ltd.
5,411.30
428.99
8.61%
IN:LUPIN
Lupin Limited
2,302.10
247.47
12.04%
IN:SUNPHARMA
Sun Pharmaceutical Industries Limited
1,747.70
-39.57
-2.21%
IN:TORNTPHARM
Torrent Pharmaceuticals Ltd
4,183.20
890.27
27.04%
IN:ZYDUSLIFE
Zydus Lifesciences Limited
911.25
33.36
3.80%
Mankind Pharma Ltd. Corporate Events
Mankind Pharma Publishes Q3 and Nine-Month FY26 Earnings Call Transcript
Feb 9, 2026
Mankind Pharma Limited has released the transcript of its investor conference call discussing financial and operational performance for the third quarter and nine months of FY26. The call, held on February 3, 2026, featured senior management inclu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.